Morningstar® Stock Report™

Regeneron Pharmaceuticals Inc REGN

Último Precio
984.64
Cambio del día
7.68|0.79%

a 14/05/2024
04:38:41 EDT | USD  Retraso mínimo: 15 minutos

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
969.80 - 1,128.00970.95 - 987.805450,479108.50Bil
Último Cierre52 Week RangeP/UDividendo %ISIN
976.96684.81 - 998.3329.07-US75886F1075

Cotización Regeneron Pharmaceuticals Inc

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
Más...
Cuenta de Resultados
Ingresos16,071.7012,172.9013,117.20
Resultado Operativo8,946.804,994.004,233.20
Resultado Neto8,075.304,338.403,953.60
Beneficio Básico por Acción76.4040.5137.05
Num Medio Acciones diluidas en circulación112114114
Balance
Activo Corriente14,014.9015,884.1019,479.20
Activos no corrientes11,419.9013,330.4013,601.00
Total Activo 25,434.8029,214.5033,080.20
Pasivo corriente3,932.503,141.303,423.40
Total Pasivo---
Capital Total18,768.8022,664.0025,973.10
Flujo de Caja
Flujo de caja operativo7,081.305,014.904,594.00
Inversiones de Capital-551.90-1,616.90-926.40
Flujo de Caja Libre6,529.403,398.003,667.60

En millones, excepto "EPS básico". La moneda es USD.

Perfil de la compañía

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Sector

Atención sanitaria

Industria

Biotecnología

Estilo de acciones

Grande-Mixto

Fin Ejercicio Fiscal

diciembre

Empleados

13,450
Principales Características
Más...
Precio/Beneficio 12 m27.06
Precio/Valor contable3.99
Precio/Ventas TTM8.47
Crec Ingresos (media 3 a)15.57
Crec BPA (media 3 a)-
Margen operativo32.27
Margen neto30.14
ROE 12 m16.26
Deuda/Fondos propios0.10
Dividendos
AntÚltimo
Fecha declaradat.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Pagadot.b.c.t.b.c.
Cantidad0.000.00
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures